Clinipace

Clinipace

Clinipace, now operating under the brand Caidya, is a global full-service contract research organization (CRO) headquartered in Morrisville, North Carolina. The company was formed to provide clinical trial services to biopharma innovators, with a focus on patient-centric solutions and operational flexibility. The firm's service offerings span early phase development, Phase II/III studies, regulatory services, pharmacovigilance, biometrics, data management, and clinical technology. It has particular depth in oncology & hematology, rare diseases, dermatology, cell and gene therapy, cardiology, and infectious diseases. Caidya conducts studies across more than 40 countries and regions, leveraging local market expertise and harmonized technologies. Confirmed areas of activity include the United States, Europe, and China. Caidya maintains at least 14 offices globally, including locations in Shanghai, Beijing, Menlo Park, and Boston. In February 2026, the company named Michael Clay as Chief Operating Officer to drive operational excellence and advance multi-regional clinical development. The same month, it appointed Mario Bautista as Head of Business Development, Europe, signaling a push into the European market. The firm also operates under an ownership culture that emphasizes access to executive leadership. A structural differentiator is Caidya's hybrid posture as a CRO that pairs full-service clinical development with a distinct emphasis on ownership mentality and direct access to executive leadership. This model is designed to reduce risk and accelerate decision-making for biopharma clients, distinguishing it from larger, more bureaucratic CROs.